Top

Published in:

Open Access 01-09-2011 | Original Article

Quality assessment of HER2 testing by monitoring of positivity rates

Authors: Harald Choritz, Guntram Büsche, Hans Kreipe, On behalf of the Study Group HER2 Monitor

Published in: Virchows Archiv | Issue 3/2011

Abstract

Interlaboratory variation in human epidermal growth factor receptor 2 (HER2) testing provides a challenge for targeted therapy in breast and gastric cancer. Assessment of positivity rates among laboratories could help monitor their performance and define reference values for positivity rates to be expected in a geographic region. Pathologists regularly determined the number of HER2-positive cases (HER2 3+, HER2 2+/amplified or amplified) in their laboratory, and figures were continuously entered into a central website. The overall positivity rate of each participant was calculated and compared with the average rates of all other institutes (n = 42). A total of 18,081 test results on breast cancer and 982 on gastric cancer were entered into the system. Positivity rates for HER2 in breast cancer ranged from 7.6% to 31.6%. Statistically, the results from six institutions qualified as outliers (p < 0.000005). From the remaining institutions encompassing 10,916 assessments, the mean proportion of positive cases was 16.7 ± 3.2% (99% confidence interval 16.6–16.8). The results from six institutions were in between the 95% and 99.5% confidence intervals. For gastric cancer, there was one outlier and the mean positivity rate was 23.2 ± 5.7%. The proportion of HER2-positive breast cancer cases is considerably lower than could have been expected from published studies. By assessing the positivity rates and comparing them with that of all breast or gastric cancers in a given population, pathologists will be alerted to a potential systematic error in their laboratory assay, causative for over- or underestimation of cancer cases suited for anti-HER2 therapy.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef

Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W et al (2002) Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852–854PubMed

Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032–3038PubMedCrossRef

Roche PC, Suman VJ, Jenkins RB et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855–857PubMed

Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef

Rhodes A, Jasani B, Anderson E et al (2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118:408–417PubMedCrossRef

Rüdiger T, Höfler H, Kreipe HH et al (2002) Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 26:873–882PubMedCrossRef

von Wasielewski R, Hasselmann S, Rüschoff J et al (2008) Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch 453:537–543PubMedCrossRef

von Wasielewski R, Mengel M, Wiese B et al (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675–682CrossRef

10.

Fitzgibbons PL, Murphy DA, Dorfman DM et al (2006) Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Arch Pathol Lab Med 130:1440–1445PubMed

11.

Tong LC, Nelson N, Tsourigiannis J et al (2011) The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol 35:545–552PubMedCrossRef

12.

Wöckel A, Kreienberg R (2008) First revision of the German S3 guideline ‘diagnosis, therapy, and follow-up of breast cancer’. Breast Care (Basel) 3:82–86

13.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef

14.

Yaziji H, Goldstein LC, Barry TS et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972–1977PubMedCrossRef

15.

Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63–69PubMedCrossRef

16.

Dinh P, de Azambuja E, Piccart-Gebhart MJ (2007) Trastuzumab for early breast cancer: current status and future directions. Clin Adv Hematol Oncol 5:707–717PubMed

17.

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRef

18.

Rüschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307PubMedCrossRef

19.

Sauter G, Lee J, Bartlett JM (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333PubMedCrossRef

20.

Dendukuri N, Khetani K, McIsaac M et al (2007) Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176:1429–1434PubMedCrossRef

21.

Rydén L, Haglund M, Bendahl PO et al (2009) Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol 48:860–866PubMed

22.

Francis GD, Dimech M, Giles L et al (2007) Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol 60:1277–1283PubMedCrossRef

23.

Mengel M, Hebel K, Kreipe H et al (2005) Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J 11:34–40PubMedCrossRef

24.

von Wasielewski R, Krusche CA, Rüschoff J et al (2008) Implementation of external quality assurance trials for immunohistochemically determined breast cancer biomarkers in Germany. Breast Care (Basel) 3:128–133CrossRef

Title: Quality assessment of HER2 testing by monitoring of positivity rates
Authors: Harald Choritz
Guntram Büsche
Hans Kreipe
On behalf of the Study Group HER2 Monitor
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 3/2011
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1132-8

At a glance: The STEP trials

Springer Medicine

Quality assessment of HER2 testing by monitoring of positivity rates

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma

The incidence of lymphocytic thyroid infiltration and Hashimoto's thyroiditis increased in patients operated for benign goiter over a 31-year period

Pachydermia verrucosa…of the (very) bad kind!

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

Lysozyme-rich mucus metaplasia in duodenal crypts supersedes Paneth cells in celiac disease

Immunohistochemical localization of autophagosomal membrane-associated protein LC3 in granular cell tumor and schwannoma